<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">RIFABUTIN</span><br/>(rif-a-bu'tin)<br/><span class="topboxtradename">Ansamycin, </span><span class="topboxtradename">Mycobutin<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">antituberculosis agent</span><br/><b>Prototype: </b>Rifampin<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>150 mg capsules</p>
<h1><a name="action">Actions</a></h1>
<p>Semisynthetic bacteriostatic antibiotic. Mode of action may be to inhibit DNA-dependent RNA polymerase (an enzyme) in susceptible
         bacterial cells but not in human cells.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Effective against, <i>Mycobacterium, avium, complex</i> (MAC) (or <i>M. avium-intracellulare</i>) and many strains of <i>M. tuberculosis</i>.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>The prevention of disseminated <i>Mycobacterium avium</i> complex (MAC) disease in patients with advanced HIV infection.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to rifabutin or any other rifamycins; lactation.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Pregnancy (category B).</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Prevention of MAC</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 300 mg q.d., may give 150 mg b.i.d. if nausea is a problem<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 75 mg q.d.<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give as usual dose of 300 mg/d or in two divided doses of 150 mg with food if needed to reduce GI upset.</li>
<li>Store at room temperature, 15°30° C (59°86° F), unless otherwise directed.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> <span class="speceff-common">Headache,</span> <span class="typehead">GI:</span> <span class="speceff-common">Abdominal pain, dyspepsia, nausea, taste perversion, increased liver enzymes.</span> <span class="typehead">Hematologic:</span> Thrombocytopenia, eosinophilia, leukopenia, <span class="speceff-life">neutropenia</span>. <span class="typehead">Skin:</span> Rash. <span class="typehead">Other:</span> <span class="speceff-common">Turns urine, feces, saliva, sputum, perspiration, and tears orange. Soft contact lenses may be permanently discolored.</span>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> May decrease levels of <span class="classification">benzodiazepines</span>, <span class="classification">beta blockers</span>, <b>clofibrate,</b> <b>dapsone,</b> <span class="classification">narcotics</span>, <span class="classification">anticoagulants</span>, <span class="classification">corticosteroids</span>, <b>cyclosporine,</b> <b>quinidine,</b> <span class="classification">oral contraceptives</span>, <span class="classification">progestins</span>, <span class="classification">sulfonylureas</span>, <b>ketoconazole,</b> <b>fluconazole,</b> <span class="classification">barbiturates</span>, <b>theophylline,</b> and <span class="classification">anticonvulsants</span>, resulting in therapeutic failure. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> 1220% of oral dose reaches the systemic circulation. <span class="typehead">Peak:</span> 23 h. <span class="typehead">Distribution:</span> 85% protein bound. Widely distributed, high concentrations in the lungs, liver, spleen, eyes, and kidney. Crosses placenta,
      distributed into breast milk. <span class="typehead">Metabolism:</span> Metabolized in the liver. Causes induction of hepatic enzymes. <span class="typehead">Elimination:</span> Approximately 53% of dose is excreted in urine as metabolites, 30% is excreted in feces. <span class="typehead">Half-Life:</span> 1696 h (average 45 h). 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor patients for S&amp;S of active TB. Report immediately.</li>
<li>Lab tests: Monitor periodic blood work for neutropenia and thrombocytopenia.</li>
<li>Evaluate patients on concurrent oral hypoglycemic therapy for loss of glycemic control.</li>
<li>Review patient's complete drug regimen because dosage adjustment of a significant number of drugs may be needed when rifabutin
            is added to regimen.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Learn S&amp;S of TB and MAC (e.g., persistent fever, progressive weight loss, anorexia, night sweats, diarrhea) and notify physician
            if any of these develop.
         </li>
<li>Notify physician of following: Muscle or joint pain, eye pain or other discomfort, chest pain with dyspnea, rash, or a flu-like
            syndrome.
         </li>
<li>Be aware that urine, feces, saliva, sputum, perspiration, tears, and skin may be colored brown-orange. Soft contact lens may
            be permanently discolored.
         </li>
<li>Rifabutin may reduce the activity of a wide variety of drugs. Provide a complete and accurate list of concurrent drugs to
            the physician for evaluation.
         </li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>